Horten Center for Patient-Oriented Research and Knowledge Transfer, University of Zurich, Zurich, Switzerland.
PLoS One. 2011;6(5):e19994. doi: 10.1371/journal.pone.0019994. Epub 2011 May 18.
With the broad availability of effective medications, identifying individuals bearing a higher risk for osteoporotic fractures has become an issue of major concern in modern medicine. In recent years various prognostic instruments have become available showing conflicting results regarding estimated risks for individual patients.
To provide an overview of current evidence and of opportunities for further research.
METHODOLOGY/PRINCIPAL FINDINGS: Systematic review: We identified studies describing the development of instruments and all subsequent validations in electronic databases and reference lists of included studies. We screened for inclusion, read full papers and extracted data on salient clinical features, performance characteristics and quality in duplicate. Searches retrieved 5,275 records of which full texts of 167 papers were obtained after screening titles and abstract. We included 35 studies enrolling a total of 609,969 patients (median 2546) reporting on 31 derivations and 12 validations after assessing full texts. Median follow-up time was 4.1 years (IQR 3 to 7.7). Only four studies validated an instrument that was developed by another group. None of the existing instruments was validated more than once. The five most frequent included variables in the final model were age, body mass index, bone mass index, past history of falls, and maternal history of fractures. The methodological quality of the studies was moderate.
There is a plethora of evidence available studying the association of risk profiles and the development of osteoporotic fractures. The small number of out-of-sample validations, the large variety of study characteristics, outcomes and follow-up periods impedes from deriving robust summaries and from conclusions regarding the clinical performance of many tools. First and foremost, future activity in this field should aim at reaching a consensus among clinical experts in respect to the existing instruments. Then we call for careful validations and expedient adaptations for local circumstances of the most promising candidates.
随着有效药物的广泛应用,确定骨质疏松性骨折风险较高的个体已成为现代医学关注的主要问题。近年来,各种预后工具已经出现,但对于个体患者的估计风险却存在相互矛盾的结果。
提供当前证据的概述,并探讨进一步研究的机会。
方法/主要发现:系统评价:我们在电子数据库和纳入研究的参考文献列表中确定了描述工具开发以及所有后续验证的研究。我们进行了筛选以纳入研究,阅读全文并提取了关于重要临床特征、性能特征和质量的双重数据。检索到 5275 条记录,经过标题和摘要筛选后,获得了 167 篇全文论文。我们纳入了 35 项研究,共纳入了 609969 名患者(中位数为 2546 人),这些研究报告了 31 项推导和 12 项验证。中位随访时间为 4.1 年(IQR 3 至 7.7)。只有四项研究验证了另一个小组开发的工具。没有一个现有工具经过多次验证。最终模型中最常见的五个包含变量是年龄、体重指数、骨密度指数、既往跌倒史和母亲骨折史。研究的方法学质量为中等。
目前有大量证据研究风险概况与骨质疏松性骨折的发生之间的关联。由于样本外验证数量较少、研究特征、结局和随访期的多样性,难以得出稳健的总结,也难以对许多工具的临床性能得出结论。首先,该领域的未来活动应旨在就现有工具达成临床专家之间的共识。然后,我们呼吁对最有前途的候选工具进行仔细验证和及时适应当地情况。